Using genetic findings in autism for the development of new pharmaceutical compounds.
| Publicado en: | Psychopharmacology Vol. 231; no. 6; pp. 1063 - 1079 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104034810&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104034810 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00333158 EJD jtl: Psychopharmacology issn: 00333158 maglogo: N pubinfo: dt: Mar2014 vid: 231 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104034810 2012483742 10.1007/s00213-013-3334-z 104034810 ppf: 1063 ppct: 16 formats: fmt: @attributes: type: P tig: atl: Using genetic findings in autism for the development of new pharmaceutical compounds. aug: au: Vorstman, Jacob Spooren, Will Persico, Antonio Collier, David Aigner, Stefan Jagasia, Ravi Glennon, Jeffrey Buitelaar, Jan affil: Department of Psychiatry, Brain Center Rudolf Magnus, A001.468, University Medical Center Utrecht, Heidelberglaan 100 3485 CX Utrecht The Netherlands sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|